ESMO - Eur. Oncology· @myESMO · X·· 15 hours agoScore70
Body
#ESMO26: Intismeran autogene individualised #mRNA-based #NeoantigenVaccine therapy reduced recurrence risk by 42% in patients with resectable #melanoma treated with adjuvant pembrolizumab in the INTerpath-001 phase III #ClinicalTrial
🔗 https://ow.ly/a6FC50ZZkJV
#InsightsbyESMO
582 views · 9 likes · 3 reposts · 0 replies
Conference abstracts
LBA1matched by Presidential Symposium I
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgSource: ESMO - Eur. Oncology · x.com